Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2141377rdf:typepubmed:Citationlld:pubmed
pubmed-article:2141377lifeskim:mentionsumls-concept:C0012931lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C0079822lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C0013080lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C0681867lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C0042210lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:2141377lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:2141377pubmed:issue14lld:pubmed
pubmed-article:2141377pubmed:dateCreated1990-7-25lld:pubmed
pubmed-article:2141377pubmed:abstractTextTo investigate the response of mentally retarded individuals (MR) with Down's syndrome (Down-MR) to recombinant hepatitis B vaccine, three doses (20 micrograms per dose) were administered on the usual schedule (months 0, 1 and 6) to two groups of MR with mean age of 14.6 years. The first group consisted of 32 MR-Down. The second group consisted of 35 MR other etiologies (non Down-MR). Both had the same sex distribution and similar ages and weight/height index. The post vaccination anti-HBs titers were measured on months 1, 2, 6 and 8. The results could be analysed in 63 MR. Eight months after vaccination, 100% of Down-MR and 91% of non Down-MR developed a response to the vaccine (anti-HBs greater than 10 IU/l). Both groups achieved high antibody titers (geometric mean 4.298 and 6.424, respectively). A significant inverse correlation of anti-HBs with age was found, but not with sex of with the weight-height index. It was concluded that Down-MR in young age have a normal response to recombinant hepatitis B vaccine at the usual dose and schedule. Therefore, the goal to suppress the reservoir of hepatitis B in Down-MR both in institutions for MR and in normal schools should be achieved.lld:pubmed
pubmed-article:2141377pubmed:languagespalld:pubmed
pubmed-article:2141377pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2141377pubmed:citationSubsetIMlld:pubmed
pubmed-article:2141377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2141377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2141377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2141377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2141377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2141377pubmed:statusMEDLINElld:pubmed
pubmed-article:2141377pubmed:monthAprlld:pubmed
pubmed-article:2141377pubmed:issn0025-7753lld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:ArriolaJ AJAlld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:CortésAAlld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:ArenasJ IJIlld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:García...lld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:CabriadaJJlld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:DorronsoroMMlld:pubmed
pubmed-article:2141377pubmed:authorpubmed-author:AlbizuIIlld:pubmed
pubmed-article:2141377pubmed:issnTypePrintlld:pubmed
pubmed-article:2141377pubmed:day14lld:pubmed
pubmed-article:2141377pubmed:volume94lld:pubmed
pubmed-article:2141377pubmed:ownerNLMlld:pubmed
pubmed-article:2141377pubmed:authorsCompleteYlld:pubmed
pubmed-article:2141377pubmed:pagination528-30lld:pubmed
pubmed-article:2141377pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:meshHeadingpubmed-meshheading:2141377-...lld:pubmed
pubmed-article:2141377pubmed:year1990lld:pubmed
pubmed-article:2141377pubmed:articleTitle[Response to recombinant DNA antihepatitis B vaccine in mentally retarded patients with Down's syndrome. A controlled study].lld:pubmed
pubmed-article:2141377pubmed:affiliationServicio de Aparato Digestivo, Hospital Nuestra Señora de Aránzazu, San Sebastián.lld:pubmed
pubmed-article:2141377pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2141377pubmed:publicationTypeEnglish Abstractlld:pubmed